Overview

A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)

Status:
Completed

Trial end date:
2012-09-01

Target enrollment:

Participant gender:

Summary

This phase III, multicenter, randomized, placebo-controlled, blinded trial is designed to evaluate the efficacy and safety of bevacizumab when combined with standard chemotherapy compared with chemotherapy alone in subjects with previously treated metastatic breast cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Bevacizumab